| Genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1 A Strange, F Capon, CCA Spencer, J Knight, ME Weale, MH Allen, ... Nature genetics 42 (11), 985, 2010 | 1018 | 2010 |
| Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists … RB Warren, CH Smith, ZZN Yiu, DM Ashcroft, JNWN Barker, AD Burden, ... Journal of Investigative Dermatology 135 (11), 2632-2640, 2015 | 427 | 2015 |
| European consensus statement on phenotypes of pustular psoriasis AA Navarini, AD Burden, F Capon, U Mrowietz, L Puig, S Köks, K Kingo, ... Journal of the European Academy of Dermatology and Venereology 31 (11), 1792 …, 2017 | 423 | 2017 |
| Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis EJ Samarasekera, JM Neilson, RB Warren, J Parnham, CH Smith Journal of Investigative Dermatology 133 (10), 2340-2346, 2013 | 316 | 2013 |
| British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017 CH Smith, ZK Jabbar‐Lopez, ZZ Yiu, T Bale, AD Burden, LC Coates, ... British Journal of Dermatology 177 (3), 628-636, 2017 | 303 | 2017 |
| Psoriasis: is the impairment to a patient’s life cumulative? AB Kimball, U Gieler, D Linder, F Sampogna, RB Warren, M Augustin Journal of the European Academy of Dermatology and Venereology 24 (9), 989-1004, 2010 | 272 | 2010 |
| The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases M Jani, A Barton, RB Warren, CEM Griffiths, H Chinoy Rheumatology 53 (2), 213-222, 2014 | 247 | 2014 |
| Identification of ZNF313 / RNF114 as a novel psoriasis susceptibility gene F Capon, MJ Bijlmakers, N Wolf, M Quaranta, U Huffmeier, M Allen, ... Human molecular genetics 17 (13), 1938-1945, 2008 | 236 | 2008 |
| Bimekizumab versus secukinumab in plaque psoriasis K Reich, RB Warren, M Lebwohl, M Gooderham, B Strober, RG Langley, ... New England Journal of Medicine 385 (2), 142-152, 2021 | 227 | 2021 |
| Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active … K Reich, KA Papp, A Blauvelt, RG Langley, A Armstrong, RB Warren, ... The Lancet 397 (10273), 487-498, 2021 | 209 | 2021 |
| Clinical and genetic differences between pustular psoriasis subtypes S Twelves, A Mostafa, N Dand, E Burri, K Farkas, R Wilson, HL Cooper, ... Journal of allergy and clinical immunology 143 (3), 1021-1026, 2019 | 207 | 2019 |
| Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis J Bowes, A Budu-Aggrey, U Huffmeier, S Uebe, K Steel, HL Hebert, ... Nature communications 6 (1), 6046, 2015 | 202 | 2015 |
| A consensus report on appropriate treatment optimization and transitioning in the management of moderate‐to‐severe plaque psoriasis U Mrowietz, E De Jong, K Kragballe, R Langley, A Nast, L Puig, K Reich, ... Journal of the European Academy of Dermatology and Venereology 28 (4), 438-453, 2014 | 192 | 2014 |
| Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study) LC Coates, T Aslam, F Al Balushi, AD Burden, E Burden‐The, ... British Journal of Dermatology 168 (4), 802-807, 2013 | 185 | 2013 |
| Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo … AW Armstrong, M Gooderham, RB Warren, KA Papp, B Strober, D Thaçi, ... Journal of the American Academy of Dermatology 88 (1), 29-39, 2023 | 180 | 2023 |
| Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study SK Mahil, N Dand, KJ Mason, ZZN Yiu, T Tsakok, F Meynell, B Coker, ... Journal of allergy and clinical immunology 147 (1), 60-71, 2021 | 172 | 2021 |
| A review of biologic therapies targeting IL-23 and IL-17 for use in moderate-to-severe plaque psoriasis M Campa, B Mansouri, R Warren, A Menter Dermatology and therapy 6, 1-12, 2016 | 167 | 2016 |
| Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis RB Warren, RL Smith, E Campalani, S Eyre, CH Smith, JNWN Barker, ... Journal of Investigative Dermatology 128 (8), 1925-1929, 2008 | 163 | 2008 |
| Bimekizumab versus adalimumab in plaque psoriasis RB Warren, A Blauvelt, J Bagel, KA Papp, P Yamauchi, A Armstrong, ... New England Journal of Medicine 385 (2), 130-141, 2021 | 161 | 2021 |
| Cumulative life course impairment in psoriasis: patient perception of disease‐related impairment throughout the life course RB Warren, CE Kleyn, WP Gulliver British Journal of Dermatology 164 (s1), 1-14, 2011 | 158 | 2011 |
